MF6 MagForce AG

DGAP-News: MagForce AG announces positive results of 2020 Annual General Meeting

DGAP-News: MagForce AG / Key word(s): AGM/EGM
MagForce AG announces positive results of 2020 Annual General Meeting

13.08.2020 / 15:00
The issuer is solely responsible for the content of this announcement.

MagForce AG announces positive results of 2020 Annual General Meeting

Berlin, Germany, and Nevada, USA, August 13, 2020 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting today in a virtual setting. The Annual General Meeting approved all resolution items with an overwhelming majority.

The CEO and Chairman of the Management Board, Dr. Ben J. Lipps, greeted attendees, via video. Thereafter, CFO, Christian von Volkmann, reported on the current operational developments and provided an overview of the 2019 fiscal year, as well as an outlook for the current year. Subsequently, he gave an update on the status of the strategic plan.

Further details of the Annual General Meeting 2020, including the Management Board presentation and voting results, are available on the MagForce website at /en/home/for-press-investors/#general_meetings.

About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of glioblastoma. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.


For more information, please visit:
Get to know our Technology:
Stay informed and subscribe to our


Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.


Contact:
Barbara von Frankenberg
Vice President Communications & Investor Relations
T 7
E-Mail:


13.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail:
Internet:
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange
EQS News ID: 1117779

 
End of News DGAP News Service

1117779  13.08.2020 

fncls.ssp?fn=show_t_gif&application_id=1117779&application_name=news&site_id=research_pool
EN
13/08/2020

Underlying

MF6MagForce AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MagForce AG

Sean Conroy
  • Sean Conroy
MF6 MAGFORCE AG

MagForce - Termination of coverage

Edison Investment Research is terminating coverage on Mercia Asset Management (MERC), Bloc Ventures (unlisted), YOC (YOC.DE), Genuit Group (GEN), AlzeCure Pharma (ALZCUR), abrdn Latin American Income Fund (ALAI), Magforce (MF6), OPG Power Ventures (OPG) and paragon (PGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

10/31/22 October 31, 2022 1 EN
Cosmin Filker
  • Cosmin Filker
MF6 MAGFORCE AG

Research Comment englisch - MagForce AG - 27.07.22

MagForce AG unexpectedly files for insolvency; price target and rating, suspended In an announcement dated 26.07.2022, MagForce AG informed the capital market, to our, complete surprise, that it intends to file for insolvency proceedings due to insolvency. According to the company's announcement, this had become necessary after reorganisationmeasures had not led to the desired cost savings. Even though the company has not yet been able to generate any significant cash inflows from its operatin...

07/28/22 July 28, 2022 4 EN
Cosmin Filker
  • Cosmin Filker
MF6 MAGFORCE AG

Research Comment - MagForce AG - 27.07.22

MagForce AG meldet überraschend Insolvenz an; Kursziel und Rating ausgesetzt Mit Meldung vom 26.07.2022 hat die MagForce AG den Kapitalmarkt, für uns komplett überraschend, darüber informiert, einen Antrag auf Eröffnung eines Insolvenzverfahrens wegen Zahlungsunfähigkeit stellen zu wollen. Gemäß Unternehmensmeldung sei dies notwendig geworden, nachdem reorganisatorische Maßnahmen nicht zu den gewünschten Kosteneinsparungen geführt haben. Auch wenn die Gesellschaft aufgrund der noch nicht erfol...

07/28/22 July 28, 2022 4 DE
Cosmin Filker
  • Cosmin Filker
MF6 MAGFORCE AG

Investment im Fokus - MagForce AG - 18.07.22

Die MagForce AG mit Sitz in Berlin ist nach eigenen Angaben ein führendes Unternehmen auf dem Gebiet der Nanomedizin mit Fokus auf der Krebstherapie. Die von ihr entwickelte NanoTherm® Therapie wäre nach Unternehmensangaben für die lokale Behandlung von nahezu allen soliden Tumoren geeignet. Die Behandlung erfolgt durch Wärme, die mittels Aktivierung von injizierten superparamagnetischen Nanopartikeln erzeugt wird. Die Bestandteile dieser Therapie, die Medizinprodukte NanoTherm®, NanoPlan®, Ther...

07/18/22 July 18, 2022 5 DE
Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann
MF6 MAGFORCE AG

Research Report (Anno) englisch - MagForce AG - 13.07.22

By its own account, MagForce AG, with its registered office in Berlin, is a leading company in the field of nanomedicine with a focus on cancer treatment. The NanoTherm® treatment developed by the company could be suitable for the local treatment of almost all solid tumours. The treatment is based on heat that is created by the activation of injected superparamagnetic nanoparticles. The components of this treatment, the medical devices NanoTherm® and NanoPlan® and the thermometric catheter TK01 ...

07/13/22 July 13, 2022 20 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch